Brazil health regulator Anvisa allows Chinese COVID-19 vaccine trial
SAO PAULO (Reuters) - Brazilian health regulator Anvisa on Friday approved clinical trials of a potential coronavirus vaccine developed by China’s Sinovac, according to an official gazette publication.
The study - first announced on June 11 - is led by Instituto Butantan, a research center funded by the state of Sao Paulo. The agreement with Sinovac includes not only trials but also the transference of technology to produce the potential vaccine locally.